CN105758783B - 一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 - Google Patents
一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 Download PDFInfo
- Publication number
- CN105758783B CN105758783B CN201610292665.3A CN201610292665A CN105758783B CN 105758783 B CN105758783 B CN 105758783B CN 201610292665 A CN201610292665 A CN 201610292665A CN 105758783 B CN105758783 B CN 105758783B
- Authority
- CN
- China
- Prior art keywords
- added
- sample
- detection
- cell
- peripheral blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000000684 flow cytometry Methods 0.000 title claims abstract description 11
- 102100027612 Kallikrein-11 Human genes 0.000 title abstract description 4
- 101710152431 Trypsin-like protease Proteins 0.000 title abstract description 4
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 13
- 239000011886 peripheral blood Substances 0.000 claims abstract description 13
- 238000010166 immunofluorescence Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 31
- 101000637853 Homo sapiens Transmembrane protease serine 11F Proteins 0.000 claims description 16
- 102100032006 Transmembrane protease serine 11F Human genes 0.000 claims description 14
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 206010018910 Haemolysis Diseases 0.000 claims description 8
- 230000008588 hemolysis Effects 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 7
- 239000003219 hemolytic agent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 239000011736 potassium bicarbonate Substances 0.000 claims description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 5
- 238000005070 sampling Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 abstract description 4
- 238000011017 operating method Methods 0.000 abstract description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010057180 Liver and spleen enlargement Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法。具体而言,该方法包括下列步骤:1)骨髓或外周血样品采集;2)免疫荧光标记;和3)上流式细胞仪检测。本发明的检测方法既可以使用少量的骨髓细胞作为样品,又可以使用外周血作为样品,极大地减轻了患者在样品采集过程中所承受的痛苦,提高了患者的顺从性。另外,本发明的检测方法中的操作步骤简单、便捷,检测周期短,仅需数小时即可完成检测,极大地缩短了检测周期,有利于加快相关研究的进度,节省了时间成本。
Description
技术领域
本发明属于生物检测技术领域,涉及一种人气道胰蛋白酶样蛋白酶4(Humanairway trypsin-like protease 4,HATL4)的检测方法,尤其涉及一种利用流式细胞术检测HATL4的方法。
背景技术
急性髓细胞性白血病(acute myeloid leukemia,AML)是由多能干细胞或由髓系细胞分化发育过程中不同阶段的造血祖细胞恶性转化所形成的一类造血系统的克隆性疾病。急性白血病中以AML最为常见,占成人白血病发病的2/3,并且随着人口老龄化而呈现出逐年增加的趋势。AML是一种具有高度异质性的疾病,发病时骨髓中异常的原始细胞及幼稚细胞(白血病细胞)大量增殖并抑制正常造血,广泛浸润肝、脾、淋巴结等各种脏器,出现贫血、发热、出血、感染和肝脾淋巴结肿大等相应的临床表现。
HATL4 mRNA在AML患者骨髓细胞中异常高表达,而在正常人外周血、正常人骨髓以及其他类型的恶性血液病(如慢性粒细胞性白血病、急性淋巴细胞性白血病、慢性淋巴细胞性白血病)患者骨髓细胞中检测不到。目前,通过实时荧光定量PCR能够检测各种白血病患者骨髓细胞中的HATL4 mRNA(参见苏州大学蒋艺枝硕士论文“Ⅱ型跨膜丝氨酸蛋白酶HATL4的表达及其单克隆抗体的研制”),但是这种方法存在所需骨髓标本量多和检测周期长等缺点。
流式细胞术(Flow cytometry,FCM)是一种集合了光学、电子学、流体力学、细胞化学、免疫学和计算机科学等多门学科和技术为一体的细胞分析技术,其不受分子生物学异常的影响,可以直观地对白血病细胞上HATL4进行准确定量分析。
发明内容
针对上述情况,本发明提供了一种利用流式细胞术检测HATL4的方法,其包括如下步骤:
(1)样品采集:选取0.1~1 mL骨髓或外周血作为样品;当以骨髓作为样品时,取髂前上棘后上方1~2 cm处作为穿刺点,取样后置于经抗凝化处理的针筒中;当以外周血作为样品时,取肘静脉处作为采血点,取样后置于经抗凝化处理的试管中;
(2)免疫荧光标记:吸取100 μL已抗凝的样品,置于样品管中,加入CD45-PerCP、CD13-PE和HATL4-FITC各10 μL混匀,并向异常细胞群中加入标志,同时向对照管中加入同型对照,然后于室温避光反应30分钟,再分别加入1 mL溶血剂,混匀后避光溶血15分钟,待完全溶血后,于2000 rpm离心5分钟,弃去上清液后,再用PBS洗涤1遍,于2000 rpm离心5分钟;
(3)检测:检测前进行三色荧光补偿,检测时用CD45-PerCP/SSC设门,用于将异常细胞群与正常细胞群分开,将异常细胞群圈出设门后,每份样品捕获分析2×104个细胞,上流式细胞仪检测。
优选的,在上述方法中,步骤(1)中所述样品为外周血。
优选的,在上述方法中,步骤(1)中所述样品的取样量为0.1 mL。
优选的,在上述方法中,步骤(1)中所述抗凝化处理采用肝素来完成。
优选的,在上述方法中,步骤(2)中所述标志按照下列方式加入:向粒细胞中加入CD13,向单核细胞中加入CD14,向淋巴细胞中加入CD19或CD3。
优选的,在上述方法中,步骤(2)中所述溶血剂按照下列方法配制:按照1 L水溶解8~9 g NH4Cl、0.5~1.5 g KHCO3和20~40 mg EDTA-2Na的比例,向水中加入NH4Cl、KHCO3和EDTA-2Na,搅拌均匀后,用0.45 μm滤膜过滤,即得。
与现有技术相比,采用上述技术方案的本发明具有如下优点:
(1)本发明的检测方法既可以使用少量的骨髓细胞作为样品,又可以使用外周血作为样品,极大地减轻了患者在样品采集过程中所承受的痛苦,提高了患者的顺从性;
(2)本发明的检测方法中的操作步骤简单、便捷,检测周期短,仅需数小时即可完成检测,极大地缩短了检测周期,有利于加快相关研究的进度,节省了时间成本。
附图说明
图1为利用流式细胞术检测HATL4在AML患者骨髓中性粒细胞表面表达的结果图,其中THP-1(急性单核细胞性白血病)为阳性对照,NPB(正常人外周血)为阴性对照(n=8,数据为其中一个结果)。
图2为利用流式细胞术检测HATL4在白血病患者骨髓单核细胞表面表达的结果图,其中THP-1为阳性对照,NPB为阴性对照(n=6,数据为其中一个结果)。
具体实施方式
下面将结合附图和具体实施例来进一步说明本发明的技术方案。除非另有说明,下列实施例中所使用的药品、试剂、仪器均可通过商业手段获得。
实施例一:采用CD45/SSC双参数散点图设门方法检测骨髓样本。
本实施例以1 mL骨髓作为样品,取髂前上棘后上方1 cm处作为穿刺点,取样后置于预先肝素化处理的5 mL针筒中抗凝,待用。
吸取100 μL已抗凝骨髓,置于实验管中,并加入CD45-PerCP、CD13-PE和HATL4-FITC各10 μL混匀,根据不同的异常细胞群加入不同的标志:向粒细胞中加入CD13,向单核细胞中加入CD14,向淋巴细胞中加入CD19、CD3,同时向对照管加入同型对照,然后于室温避光反应30 min,加1 mL溶血剂(向1 L水中加入8 g NH4Cl、1 g KHCO3和30 mg EDTA-2Na,搅拌均匀后,用0.45 μm微孔滤膜过滤,即得),混匀后避光溶血15 min,待完全溶血后,于2000rpm离心5 min,弃去上清液后,再用PBS洗涤1遍,于2000 rpm离心5 min,待测。
检测前进行三色荧光补偿,检测时用CD45-PerCP/SSC设门,将异常细胞群圈出设门,每份样品捕获分析2×104个细胞,上流式细胞仪(FACS Calibur,美国BD Biosciences公司)检测,完成HATL4的检测过程。
通过流式细胞术检测HATL4蛋白在AML患者骨髓细胞中的表达情况,其结果如图1和图2所示。从图1中可知,CD13是THP-1细胞和中性粒细胞的表面标志,以THP-1细胞为阳性对照,NPB中的中性粒细胞为阴性对照,AML患者骨髓中的中性粒细胞上都有HATL4蛋白的表达,阳性率为100%。从图2中可知,CD14是单核细胞的表面标志,以THP-1细胞为阳性对照,NPB中的单核细胞为阴性对照,AML患者骨髓中的单核细胞上都有HATL4蛋白的表达,阳性率为100%。
实施例二:采用CD45/SSC双参数散点图设门方法检测外周血样本。
本实施例以1 mL外周血作为样品,取样后置于预先肝素化处理的5 mL试管中抗凝,待用。
吸取100 μL已抗凝外周血,置于实验管中,并加入CD45-PerCP、CD13-PE和HATL4-FITC各10 μL混匀,根据不同的异常细胞群加入不同的标志:向粒细胞中加入CD13,向单核细胞中加入CD14,向淋巴细胞中加入CD19、CD3,同时向对照管加入同型对照,然后于室温避光反应30 min,加1 mL溶血剂(制法同上),混匀后避光溶血15 min,待完全溶血后,于2000rpm离心5 min,弃去上清液后,再用PBS洗涤1遍,于2000 rpm离心5 min,待测。
检测前进行三色荧光补偿,检测时用CD45-PerCP/SSC设门,将异常细胞群圈出设门,每份样品捕获分析2×104个细胞,上流式细胞仪(FACS Calibur,美国BD Biosciences公司)检测,完成HATL4蛋白在AML患者外周血白细胞中表达情况的检测。
由上述实施例可以看出,本发明的检测方法既可以使用少量的骨髓细胞作为样品,又可以使用外周血作为样品,极大地减轻了患者在样品采集过程中所承受的痛苦,提高了患者的顺从性;另外,本发明的检测方法中的操作步骤简单、便捷,检测周期短,仅需数小时即可完成检测,极大地缩短了检测周期,有利于加快相关研究的进度,节省了时间成本。
Claims (3)
1.一种利用流式细胞术检测HATL4的方法,其包括如下步骤:
1)样品采集:选取0.1 mL外周血作为样品;当以外周血作为样品时,取肘静脉处作为采血点,取样后置于经抗凝化处理的试管中;
2)免疫荧光标记:吸取100 μL已抗凝的样品,置于样品管中,加入CD45-PerCP、CD13-PE和HATL4-FITC各10 μL混匀,并向异常细胞群中加入标志,同时向对照管中加入同型对照,然后于室温避光反应30分钟,再分别加入1 mL溶血剂,混匀后避光溶血15分钟,待完全溶血后,于2000 rpm离心5分钟,弃去上清液后,再用PBS洗涤1遍,于2000 rpm离心5分钟;
3)检测:检测前进行三色荧光补偿,检测时用CD45-PerCP/SSC设门,用于将异常细胞群与正常细胞群分开,将异常细胞群圈出设门后,每份样品捕获分析2×104个细胞,上流式细胞仪检测;
步骤2)中所述溶血剂按照下列方法配制:按照1 L水溶解8~9 g NH4Cl、0.5~1.5 gKHCO3和20~40 mg EDTA-2Na的比例,向水中加入NH4Cl、KHCO3和EDTA-2Na,搅拌均匀后,用0.45 μm滤膜过滤,即得。
2.根据权利要求1所述的方法,其特征在于:
步骤1)中所述抗凝化处理采用肝素来完成。
3.根据权利要求1所述的方法,其特征在于:
步骤2)中所述标志按照下列方式加入:向粒细胞中加入CD13,向单核细胞中加入CD14,向淋巴细胞中加入CD19或CD3。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292665.3A CN105758783B (zh) | 2016-05-05 | 2016-05-05 | 一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292665.3A CN105758783B (zh) | 2016-05-05 | 2016-05-05 | 一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105758783A CN105758783A (zh) | 2016-07-13 |
CN105758783B true CN105758783B (zh) | 2019-07-26 |
Family
ID=56322607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610292665.3A Active CN105758783B (zh) | 2016-05-05 | 2016-05-05 | 一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105758783B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108073547B (zh) * | 2017-12-06 | 2021-05-18 | 苏州大学 | 一种基于能量耗散的溶血经验预测方法及装置 |
CN111521587A (zh) * | 2020-04-24 | 2020-08-11 | 中国烟草总公司四川省公司 | 一种细胞内络氨酸磷酸化水平的检测方法 |
CN111504965A (zh) * | 2020-04-24 | 2020-08-07 | 中国烟草总公司四川省公司 | 一种流式细胞仪检测细胞内超氧化物的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103675277A (zh) * | 2013-11-12 | 2014-03-26 | 浙江大学 | 流式细胞术鉴别诊断横纹肌肉瘤与神经母细胞瘤骨髓转移及白血病的荧光探针及试剂盒 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014198843A1 (en) * | 2013-06-12 | 2014-12-18 | F. Hoffmann-La Roche Ag | Markers for responsiveness to anti-cd44 antibodies |
CN103604919A (zh) * | 2013-11-05 | 2014-02-26 | 复旦大学附属华山医院 | 一种检测人外周血中t淋巴细胞活化期标记物的方法 |
CN104360053B (zh) * | 2014-09-22 | 2016-08-17 | 重庆医科大学附属儿童医院 | 一种b淋巴细胞免疫分型的方法和试剂盒 |
CN104897630B (zh) * | 2015-05-18 | 2017-12-08 | 四川新生命干细胞科技股份有限公司 | 一种检测人精子活力的方法 |
CN105223360B (zh) * | 2015-08-28 | 2017-03-22 | 北京大学人民医院 | 鉴别检测正常浆细胞和克隆性浆细胞的试剂盒及其应用 |
-
2016
- 2016-05-05 CN CN201610292665.3A patent/CN105758783B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103675277A (zh) * | 2013-11-12 | 2014-03-26 | 浙江大学 | 流式细胞术鉴别诊断横纹肌肉瘤与神经母细胞瘤骨髓转移及白血病的荧光探针及试剂盒 |
Non-Patent Citations (1)
Title |
---|
多参数流式细胞术对外周血白血病免疫分型的研究;张锑等;《细胞与分子免疫学杂志》;20040430;第225-227页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105758783A (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Microfluidic isolation of platelet-covered circulating tumor cells | |
CN103911345B (zh) | 用于外周血中循环肿瘤细胞捕获的免疫磁性微球 | |
CN105758783B (zh) | 一种利用流式细胞术检测人气道胰蛋白酶样蛋白酶4的方法 | |
JP6757981B2 (ja) | 微少流体を用いる白血球および微小粒子分画 | |
CN103940997B (zh) | 一种乳腺癌循环肿瘤细胞检测系统及试剂盒 | |
CN109486653A (zh) | 基于微流控和免疫磁分离双重策略的痕量细胞捕获系统 | |
Begemann et al. | Atlas of clinical hematology | |
CN108795869A (zh) | 一种循环肿瘤细胞阳性富集方法 | |
CN103725648A (zh) | 一种新的循环肿瘤细胞富集技术及试剂盒制备方法 | |
Shin | Unexpected red cell antibody detection by conditional combination of LISS/Coombs and NaCl/Enzyme gel tests at a tertiary care hospital in Korea: a 5-year study | |
CN108795692A (zh) | 稀有细胞捕获系统及其应用 | |
CN107525920B (zh) | 聚离子液体磁性纳米复合物及其对痕量循环肿瘤细胞特异性富集和检测的应用 | |
CN108546676A (zh) | 隧道磁场技术分离和富集外周血中稀有细胞的方法 | |
Mackin et al. | Effects of vincristine and prednisone on platelet numbers and function in clinically normal dogs | |
US20140309553A1 (en) | Kits and methods for separating a target analyte from a suspension | |
Johnsen et al. | Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation | |
Azouna et al. | Immunophenotyping of hematopoietic progenitor cells: comparison between cord blood and adult mobilized blood grafts | |
CN110004062B (zh) | 分选富集数量极稀少循环肿瘤细胞的装置和方法 | |
JPS6011166A (ja) | 臨床検査用血漿の採取方法 | |
CN103675277B (zh) | 流式细胞术鉴别诊断横纹肌肉瘤与神经母细胞瘤骨髓转移及白血病的荧光探针及试剂盒 | |
JP6244589B2 (ja) | 微粒子分離用マイクロ流路チップ、移流集積ユニット、微粒子分離用システム及び微粒子分離方法 | |
US20120164747A1 (en) | Method of extracting plasma by agglutination of blood cells and plasma separation device therefor | |
US20100173403A1 (en) | Non-isopycnic cell purification using percoll | |
CN101726582A (zh) | 促凝类试管标本过滤方法 | |
CN107102127B (zh) | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |